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Abstract Crigler-Najjar (CN) disease is caused by a deficiency 
of the hepatic enzyme, bilirubin UDP-glucuronosyltransferase 
(B-UGT). We have found two CN type II patients, who were 
homozygous for a leucine to arginine transition at position 15 of 
B-UGT1. This mutation is expected to disrupt the hydrophobic 
core of the signal peptide of B-UGT1. Wild type and mutant B- 
UGT cDNAs were transfected in COS cells. Mutant and wild 
type mRNA were formed in equal amounts. The mutant protein 
was expressed with 0.5% efficiency, as compared to wild type. 
Mutant and wild type mRNAs were translated in vitro. Wild type 
transferase is processed by microsomes, no processing of the 
mutant protein was observed. 
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1. Introduction 
Bilirubin is the toxic breakdown product of the protopor- 
phyrin part of the heme group of proteins uch as hemoglobin 
and cytochromes. Bilirubin is conjugated with glucuronic acid 
in the liver, and the resulting water soluble bilirubin glucur- 
onides are excreted into bile, and subsequently the feces. Glu- 
curonidation of bilirubin is catalyzed by the hepatic enzyme 
bilirubin UDP-glucuronosyltransferase (B-UGT) (EC 
2.4.1.17) [1]. 
Crigler-Najjar disease (CN) is an autosomal recessive inher- 
ited disease, caused by the complete or partial absence of B- 
UGT. CN disease is characterized by high serum levels of 
unconjugated bilirubin, which, when not treated, ultimately 
leads to brain damage and death [2]. Two subtypes of CN 
disease xist; patients with type I CN have no detectable B- 
UGT activity. Type II CN is less severe, patients have residual 
B-UGT activity and serum bilirubin levels can usually be 
lowered by treatment with phenobarbital [2,3]. 
UDP-glucuronosyltransferases (UGT) are a family of pro- 
teins involved in the detoxification of many endo- and exo- 
genous substances. UGTs are anchored to the endoplasmic 
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reticulum (ER) membrane by a single hydrophobic helix lo- 
cated near the carboxyl terminus of the protein. A short car- 
boxyl terminal stretch of amino acids is thought o be exposed 
to the cytoplasm. The bulk of the protein, including the active 
site, is thought to be oriented towards the lumen of the ER 
[4,5]. B-UGT is encoded by a complex gene, UGT1, from 
which at least six different isoforms, UGT1A to UGT1F, 
are generated by a mechanism of alternative splicing [1,6,5]. 
Signal peptides fulfil a critical role in the targeting of pro- 
teins to the ER and translocation of proteins across the ER 
membrane. One of the common features of signal peptides is a 
hydrophobic ore of at least six amino acids. The signal rec- 
ognition particle (SRP) interacts with the hydrophobic region 
of the signal peptide of the growing nascent polypeptide. The 
translation stops and the complex of ribosome, SRP, and 
nascent chain is targeted to the ER. At the ER membrane, 
SRP interacts with a receptor, and protein synthesis continues 
with simultaneous translocation of the protein across the ER 
membrane [7,8]. 
Rat liver UGTs are processed by microsomes; they are 
glycosylated, and possess a cleavable signal peptide [9,10]. 
When a human phenol UGT, the UGT1F gene product, 
was expressed in Escherichia coli, cleavage of a signal peptide 
by bacterial signal peptidase occurred [1 I]. Human B-UGT1, 
the UGT1A gene product, is glycosylated [12], and a signal 
peptide of 27 amino acids is predicted. 
Signal peptide mutations that cause human disease have 
thus far only been identified in the secretory proteins: prepro- 
vasopressin [13], preproparathyroid hormone [ 14,15], and coa- 
gulation factor X [16]. In vasopressin and factor X, mutations 
were found respectively in the -1  and -3  positions of the 
carboxyl terminus of the signal peptide. These mutations 
block the cleavage of signal peptide by signal peptidase but 
not targeting and translocation across the ER membrane. In 
parathyroid hormone a mutation has been found which dis- 
rupts the hydrophobic ore of the signal peptide, and which 
has been shown to block targeting and translocation across 
the ER membrane. 
We found two CN type II patients who were homozygous 
for the same signal peptide mutation. The mutation is ex- 
pected to give rise to a leucine to arginine substitution, at 
position 15 in the middle of the hydrophobic ore of the 
predicted B-UGT1, UGT1A, signal peptide. CN disease 
caused by the 15-Arg/B-UGT mutation is inherited in an 
autosomal recessive manner, and causes a relatively mild 
form of hyperbilirubinemia. The mutation in the signal pep- 
tide of B-UGT inhibits translocation of the nascent chain 
across the ER membrane. 
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2. Materials and methods 
2.1. Chemicals 
Bilirubin and cell dissociation solution was from Sigma, St. Louis, 
MO, USA. nitroblue tetrazolium, 5-bromo,4-chloro,3-indolyl phos- 
phate, goat anti-mouse immunoglobulins conjugated with alkaline 
phosphatase were from Biorad, Veenendaal, The Netherlands. Nitro- 
cellulose membranes for Western blotting, 0.45 p.m pore size, were 
from Schleicher and Schuell, Dassel, Germany. 
pSVK3 vector was from Pharmacia, Woerden, The Netherlands. 
Restriction enzymes, T7 capscribe kit, rabbit reticulocyte lysate in 
vitro translation kit, and dog pancreatic microsomes were from Boeh- 
ringer, Mannheim, Germany. Tritiated leucine, specific activity 4.4~ 
7.0 TBq/mmol, [32p]ATP, specific activity 110 TBq/mmol, Amplify, 
and Hybond-N+ membranes for Northern blotting were from Amer- 
sham, Amersham, UK. Random primer DNA labelling system was 
from Gibco BRL, Breda, The Netherlands. 
All other chemicals were of analytical grade and were obtained 
from Merck, Darmstadt, Germany. 
2.2. Detection of mutations 
Chromosomal DNA from the parents of the CN patients was iso- 
lated from blood, and a 1220 bp fragment comprising part of exon 1 
of B-UGT1 (UGT1A), and the promoter egion, was amplified using 
PCR. Sequence of the primers: 
1CGTTTCATGAAGGTCTTGGAG 
2GGTCTATATACGACTCGTTC 
The signal peptide mutation was initially detected by sequencing of 
both strands, as described [17]. The presence of the mutation was 
confirmed using the MspI restriction site polymorphism introduced 
by the mutation. When a MspI site is introduced by the mutation, 
restriction of the PCR fragment with MspI yields fragments of 300 
and 920 bp. 
2.3. In vitro transcription and translation 
For the synthesis of mRNA, the cDNA encoding B-UGT1, 
UGT1A, was cloned in the pSVK3 vector. This vector has a SV40 
promoter for eukaryotic expression and a T7 promoter for the gen- 
eration of mRNAs. Site directed mutagenesis was performed as de- 
scribed previously [17,18]. 
B-UGT/pSVK3 was linearized with HindlII, which cuts in the 
cDNA 400 bp downstream of the termination codon, and capped 
mRNA was generated using the T7 capscribe kit from Boehringer, 
Mannheim. In vitro transcribed mRNAs were translated with reticu- 
locyte membranes in the presence of tritiated leucine, according to the 
instructions supplied by the manufacturer. 
SDS PAGE was performed according to standard techniques, as 
described [3]. The gels were fixed and soaked in Amplify for 20 min, 
to increase sensitivity. After drying, fluorograms were made by expos- 
ing Kodak Biomax MR film (Eastman Kodak, Rochester, NY, USA) 
for up to 2 weeks to the dried gels. 
2.4. Transient expression in COS-7 cells 
For the expression studies in COS-7 cells, the B-UGT cDNA was 
subcloned in the pCMV4 vector [19]. In this vector the expression is
driven by the CMV promoter, in addition a translational enhancer is 
present. Expression levels with pCMV4 were consistently higher than 
with pSVK3 (results not shown). COS-7 cells were transfected using 
DEAE dextran as described previously [3]. COS-7 cell homogenates 
were subjected to SDS PAGE and Western blotting with a monoclo- 
hal antibody directed against human UGT1, as described [3]. B-UGT 
activity was measured using HPLC, as described [3]. Microsomes were 
prepared from COS-7 cells as described previously [3,12]. ~-Galacto- 
sidase activity was determined in cell homogenates according to [20]. 
In all cases mock transfected or untransfected COS-7 cells were used 
as a control. 
RNA was extracted from the COS-7 cells transfected with B-UGT 
by the method of Chomczinsky et al. [21]. RNAs were stored at 
-70°C. The RNAs, 20 ~tg per lane, were separated on a 1.2% agarose 
gel containing 7% formaldehyde, and stained with ethidium bromide 
to determine intactness of the ribosomal RNA. The separated RNA 
was transferred to Hybond-N+ according to [20]. The blots were 
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hybridized for 16 h with a [32P]ATP labelled 2100 bp B-UGT 
cDNA fragment, at 65°C in: 0.5 M sodium phosphate buffer, pH 
7.5, 7% (w/v) SDS and 1 mM EDTA. Labelling of the eDNA probe 
with [32P]ATP was performed with a random primer DNA labelling 
kit from Gibco BRL. After the hybridization, the blots were washed 
with 0.2× SSC, 0.1% SDS at 65°C. Autoradiographs were made by 
exposing the blot to Kodak Biomax MR film for 4 h. 
3. Results 
3.1. Patients 
Two unrelated CN type II patients, who were homozygous 
for the same mutation, were found. A clinical description of 
both patients was given in [22], where the patients were des- 
ignated 8 (patient A), and 9 (patient B). This study was ap- 
proved by the medical ethical committee of the hospital. In 
the first month of life, patients A and B had serum bilirubin 
concentrations of 286+44 and 286+ 16 respectively. Serum 
bilirubin of the patients currently is 195+2 ~tM, patient A, 
and 197 +3 p.M, patient B. Both patients are treated with 
phenobarbital, and patient A also receives phototherapy. 
Treatment with phenobarbital reduced serum bilirubin by 
49% and 71% respectively. 
Bile of both patients was analyzed with HPLC to determine 
the presence of bilirubin conjugates [22]. Bile of patient A 
contained 49% bilirubin monoglucuronide and 10% bilirubin 
diglucuronide, bile of patient B contained 27% monoglucu- 
ronide and 14% diglucuronide. The percentage of unconju- 
gated bilirubin was 41% in patient A, and 59% in patient B. 
In healthy subjects all bilirubin in bile is conjugated, and more 
than 70% of bilirubin is present as diglucuronides. The bile 
analysis of the patients indicates that low B-UGT activity is 
present in the liver of both patients. 
Both patients had a T to G transition at nucleotide 44 of 
the B-UGT1 gene; this mutation causes a leucine to arginine 
transition at amino acid 15. In Fig. 1 the nucleotide and 
amino acid sequences of the postulated signal peptides of 
wild type B-UGT and 15-Arg/B-UGT are shown. The amino 
acids comprising the hydrophobic core are underlined. The 
arginine introduces a positive charge in the hydrophobic 
core of the mutant signal peptide. 
A 1220 bp fragment of the 5' region of the B-UGT1 coding 
sequence was amplified with PCR, from genomic DNA of the 
patients' parents. Because the mutation introduces an MspI 
site at position 300 of the PCR fragment, the presence of the 
mutation could easily be confirmed. Both pairs of parents 
were heterozygous for the mutation. Since the parents did 
not have elevated serum bilirubin concentrations, and bile of 
the parents contained normal amounts of bilirubin glucuro- 
nides [22], we concluded that the CN disease caused by the 15- 
Arg/B-UGT mutation is inherited in a recessive manner. 
3.2. Expression of  wild type and 15-Arg/B-UGT in COS-7 cells 
Expression of 15-Arg/B-UGT in COS-7 cells resulted in low 
but significant levels of B-UGT activity. Western blotting was 
performed with the monoclonal antibody WP1 [23], which 
recognizes human B-UGT. In homogenates of COS-7 cells 
transfeeted with wild type B-UGT (lane marked wt), a 51 
kDa protein is detected, in homogenates of COS-7 cells trans- 
fected with 15-Arg/B-UGT (lane marked mut), no B-UGT 
could be detected (Fig. 2A). B-UGT assays of homogenates 
of COS-7 cells transfected with 15-Arg/B-UGT consistently 
showed a low amount of enzyme activity. To establish 
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1, Start pre B-UGT 27, end signal peptide 
$ $ 
Wild type B-UGT 
Met Ala Val Glu Ser Gin Gly Gly Arg Pro Leu Val Leu GIv Leu Leu Leu Cvs Val Leu GIv Pro Val Val Sar His Ala 
t 
atg gct gtg gag tcc cag ggc gga cgc cca ctt gtc ctg ggc c g ctg ctg tgt gtg ctg ggc cca gtg gtg tcc cat gct 
g 
Met Ala Val Glu Ser Gin Gly Gly Arg Pro Leu Val Leu GIv Arg Leu Leu Cvs Val Leu GIv Pro Val Val Ser His Ala 
Mutant B-UGT 
Fig. 1. Nucleotide and amino acid sequence of the predicted signal peptide regions of wild type and 15-Arg/B-UGT. The residues comprising 
the hydrophobic core of the signal peptide are underlined. 
whether the mutant enzyme was membrane bound, we pre- 
pared microsomes from the transduced COS-7 cells. The B- 
UGT activity was present in the microsomal fraction of the 
COS-7 cells transfected with wild type and 15-Arg/B-UGT 
(results not shown). This indicates that the mutant enzyme 
is present in its normal subcellular localization. In enzyme 
assays with homogenates from COS-7 cells transfected with 
wild type B-UGT 15+ 1% monoglucuronide and 1.6+0.7% 
diglucuronide were formed. In incubations with 15-Arg/B- 
UGT, only bilirubin monoglucuronides were formed. To de- 
termine the precise amount of residual expression of the 15- 
Arg/B-UGT protein we performed co-expression studies. Nor- 
mal or mutant B-UGT cDNAs were expressed in COS-7 cells 
together with a plasmid containing the Escherichia coli ~l-ga- 
lactosidase gene. ~-Galactosidase and B-UGT activity were 
measured in COS-7 cell homogenates, and the expression level 
of B-UGT was corrected for the expression of [3-galactosidase. 
Values were obtained from two independent experiments. Ac- 
tivity of the 15-Arg/B-UGT was 0.5%, with a range of 0.4-- 
0.6%, of the activity of wild type enzyme. 
To determine whether the reduced expression of 15-Arg/B- 
UGT was due to a defect at the transcriptional or transla- 
tional level, we performed Northern blot analysis of RNA 
isolated from COS-7 cells transfected with normal or mutant 
B-UGT (Fig. 2B). B-UGT mRNA was detected using a 2.1 kb 
probe complementary to B-UGT cDNA. Comparable 
amounts of B-UGT messenger RNAs were detected in cells 
transfected with wild type B-UGT, and 15-Arg/B-UGT (lanes 
marked wt and mut respectively). The defect in the patients 
with the 15-Arg/B-UGT mutation is therefore not caused by a 
pretranslational mechanism affecting mRNA levels. 
3.3. In vitro transcription and translation of wild type and 
15-Arg/B-UGT 
Wild type and mutant mRNA were generated by in vitro 
transcription of pSVK3 vectors which contained the mutant 
or wild type B-UGT cDNAs. The integrity of the in vitro 
transcribed mRNAs was confirmed by agarose gel electro- 
phoresis. The mRNAs were translated into the corresponding 
polypeptides by in vitro translation with rabbit reticulocyte 
lysates and tritiated leucine. In the absence of microsomes, 
wild type and mutant B-UGT were translated with the same 
efficiency, and yielded proteins with identical molecular 
weights (lanes marked wt and mut respectively). When dog 
pancreatic microsomes were added to the in vitro translation 
mixture, the wild type protein was processed and multiple 
protein bands were detected (lane marked wt rout). One 
band of lower molecular weight was observed which could 
reflect the precursor from which the signal peptide has been 
cleaved off. The bands of higher molecular weight probably 
represent intermediate glycosylation products. In vitro trans- 
lations with the mutant protein showed no processing (lane 
marked mut mic), and a reduced incorporation of label was 
consistently seen (Fig. 3). However, if 0.5% of the mutant 
protein was processed by microsomes, this would probably 
be below the detection limit of our autoradiograms. The 
translation products were dependent on the addition of 
RNA (in the lane marked - ) ,  no RNA was added to the 
translation mixture. When control ]3-globin mRNA was added 
to the translation mixture (lane marked +), a protein with the 
expected molecular mass of 16.5 kDa was generated. 
4. Discussion 
We have shown that a leucine to arginine transition at 
amino acid 15, in the middle of the hydrophobic ore of the 
signal peptide of B-UGT, results in a strongly reduced expres- 
sion of the mutant protein. By expression of wild type and 
mutant B-UGT eDNA in COS-7 cells, we were able to show 
that the mutant protein is expressed at a level of 0.5%, com- 
pared to that of wild type B-UGT. While transcription of 
both cDNAs in COS-7 ceils was equal, in vitro translation 
of wild type and mutant mRNAs revealed that the mutant 
mRNA is not processed by microsomes. The reduced expres- 
sion of the 15-Arg/B-UGT in the patient is therefore caused 
by a reduced translation of the mutant mRNA, or by im- 
paired targeting of the mutant protein to the ER, followed 
by degradation of the mutant protein. In vitro translation of 
the mutant mRNA, in the absence of microsomes, was nor- 
mal, but strongly reduced in the presence of microsomes. This 
suggests that the decreased expression of the mutant protein is 
caused by an impaired interaction of the mutant protein with 
the ER translocation machinery. Indirect evidence suggests 
that the mutant protein is present in the ER; B-UGT activity 
in COS-7 cells transfected with mutant and wild type B-UGT 
was recovered in the microsomal fraction. These data corre- 
late with the observations made in the patients. The CN pa- 
tients homozygous for the 15-Arg/B-UGT mutation had the 
relatively benign CN type II phenotype. Since bile from the 
patients contained bilirubin glucuronides, some hepatic B- 
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A Western blot 
mut wt con 
51 kDa 
B Northern blot 
mut wt con 
2.1 kb-*  
* -28S  
* -18S  
Fig. 2. Western and Northern blots of COS-7 ceils transfected with 
wild type and 15-arg/B-UGT. COS-7 cells were transfected with 
wild type and 15-Arg/B-UGT, and processed for Western and 
Northern blotting as described in Section 2. A monoclonal ntibody 
against human UGT was used to detect B-UGT on the Western 
blot. For detection on the Northern blot a probe comprising the 
complete B-UGT cDNA, labelled with [32P]ATP, was used. COS-7 
cell protein and RNA were isolated from parallel transfections. In 
the Western blot, 50 gg protein was applied to each lane. In the 
Northern blot, 20 ~tg total RNA was applied to each lane: mut, 
COS-7 transfected with 15-Arg/B-UGT; wt, COS-7 transfected with 
wild type B-UGT; con, COS-7 mock transfected. Only COS-7 cells 
transfected with wild type B-UGT show immunoreactivity. Wild 
type and 15-Arg/B-UGT DNA are transcribed with equal efficiency 
in COS-7 cells. 
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described in this study, B-UGT expression is therefore prob- 
ably less than 4.4%, which agrees with the 0.5% residual ac- 
tivity we measured in COS-7 cells. 
Three naturally occurring mammalian signal peptide muta- 
tions have been described to date. These mutations were 
found in the secretory proteins, vasopressin, factor X, and 
parathyroid hormone [13-16]. The signal peptide mutation 
described in preparathyroid hormone was similar to the 15- 
Arg/B-UGT mutation, a disruption of the hydrophobic core 
of the signal peptide. Both in vitro translation and expression 
of the mutant parathyroid hormone in COS-7 cells showed 
that the introduction of a single arginine in the hydrophobic 
core of the signal peptide did not completely inhibit proces- 
sing. Only when an additional arginine was introduced in the 
hydrophobic ore, processing was abolished completely [15]. 
In B-UGT, the introduction of a single arginine in the hydro- 
phobic core of the signal peptide already strongly inhibits 
processing of the mutant protein. This discrepancy could be 
due to positional effects of the introduction of a positive 
charge, or to the different nature of the proteins. Besides the 
fact that parathyroid hormone is a secretory protein and B- 
UGT a membrane protein, the other obvious difference be- 
tween parathyroid hormone and B-UGT is the size. Parathyr- 
oid hormone has 109 amino acids, and B-UGT is comprised 
of 533 amino acids. It has been shown that small proteins can 
be imported cotranslationally into the ER via an SRP/ribo- 
some independent pathway [24]. The relatively high import of 
the mutant parathyroid hormone as compared to the import 
of 15-Arg/B-UGT could be due to the fact that the mutant 
parathyroid hormone can take the SRP/ribosome independent 
pathway whereas 15-Arg/B-UGT, because of its large size, 
cannot ake this pathway. 
[MW]  - + wt  wt  mut  mut  
mic  mie 
55 kD - 
16.5  kD - 
UGT expression was present. The observation that the pa- 
tients can form bilirubin glucuronides i another indication 
that the residual B-UGT expressed in these patients is present 
in its normal subcellular localization. 
We have previously described a CN type II patient with 
4.4% residual activity, who had serum bilirubin levels between 
85 gM and 194 gM in the first year of his life. [3]. The pa- 
tients from this study both had serum bilirubin concentrations 
of 286 gM in the first year of their lives. In the patients 
Fig. 3. In vitro translation of wild type and 15-Arg/B-UGT mRNA, 
in the presence and absence of microsomes. Wild type and mutant 
capped B-UGT mRNAs were translated and analyzed with SDS 
PAGE and autoradiography, as described in Section 2. - ,  no 
RNA; +, control I]-globin mRNA; wt, wild type B-UGT mRNA; 
mut, 15-Arg/B-UGT mRNA; wt mic, wild type B-UGT mRNA, 
dog pancreatic micrnsomes; mut mic, 15-Arg/B-UGT mRNA, dog 
pancreatic microsomes. Translation of wild type and mutant B- 
UGT mRNA, in the absence of microsomes, yields proteins with 
identical molecular weights. Only wild type B-UGT is processed by 
dog pancreatic microsomes. 
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